Jagannadha Avasarala is a Neurology physician affiliated with University of Kentucky. OpenAlex indexes 107 publications with 924 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Diagnosis of ON With or Without MS or NMOSD
Sponsor: Jagannadha R Avasarala
- MS and NMOSD in African-Americans
Sponsor: Jagannadha R Avasarala
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.1%CD20-directed Cytolytic Antibody36.8%Kesimpta Pen100%Part D≥22 patientsOther immunosuppressants6%Vumerity34%Dimethyl Fumarate34%Tecfidera31%Part D<11 patients+ 2 more classes in this area
Nervous system
40.4%Gabapentinoids23.8%Gabapentin76%Pregabalin24%Part D<11 patientsPotassium Channel Blocker5.7%Dalfampridine Er100%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
8.4%gamma-Aminobutyric Acid-ergic Agonist6.5%Baclofen100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist1.9%Tizanidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
David Moliterno, MD
University of Kentucky
Robert Dipaola
University of Kentucky
Darwin Conwell, MD
University of Kentucky
John Villano
University of Kentucky
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”